Health Technology Hisamitsu Pharmaceutical Co., Inc. Business Summary
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
Financial Highlights
Feb 2022
JPY USD Revenue 120,193M 1,077.96M Gross Profit 70,067M 628.40M Operating income 9,337M 83.74M Income before tax 12,956M 116.19M Net income 9,658M 86.61M EBITDA 13,658M 122.49M Diluted EPS 118.83 1.06 Dividends Per Share 84 0.75 Total Assets 302,858M 2,629.54M Total liabilities 47,969M 416.48M Total equity 253,168M 2,198.11M Operating cash flow 19,199M 172.18M Currency in JPY Currency in USD
Historical Data Feb 2018 Feb 2019 Feb 2020 Feb 2021 Feb 2022 Revenue
147,870M
143,408M
140,992M
114,510M
120,193M
Gross Profit
92,182M
88,681M
87,604M
69,173M
70,067M
Operating income
26,346M
22,280M
22,729M
10,672M
9,337M
Income before tax
27,694M
25,673M
26,155M
12,197M
12,956M
Net income
19,120M
19,204M
18,694M
9,251M
9,658M
EBITDA
32,351M
28,022M
26,980M
14,751M
13,658M
Diluted EPS
228.34
229.85
227.29
113.10
118.83
Dividends Per Share
82
82.50
83
83.50
84
Total Assets
299,913M
295,786M
307,401M
299,861M
302,858M
Total liabilities
54,681M
47,154M
56,652M
46,048M
47,969M
Total equity
244,000M
247,334M
249,276M
252,299M
253,168M
Operating cash flow
30,453M
15,772M
27,395M
5,289M
19,199M
Feb 2018 Feb 2019 Feb 2020 Feb 2021 Feb 2022 Revenue
1,327.30M
1,298.05M
1,293.38M
1,080.68M
1,077.96M
Gross Profit
827.44M
802.69M
803.63M
652.81M
628.40M
Operating income
236.48M
201.66M
208.50M
100.71M
83.74M
Income before tax
248.58M
232.37M
239.93M
115.10M
116.19M
Net income
171.62M
173.82M
171.48M
87.30M
86.61M
EBITDA
290.38M
253.63M
247.50M
139.21M
122.49M
Diluted EPS
2.04
2.08
2.08
1.06
1.06
Dividends Per Share
0.73
0.74
0.76
0.78
0.75
Total Assets
2,810.67M
2,657.07M
2,849.86M
2,814.53M
2,629.54M
Total liabilities
512.45M
423.58M
525.21M
432.21M
416.48M
Total equity
2,286.67M
2,221.82M
2,310.99M
2,368.11M
2,198.11M
Operating cash flow
273.35M
142.75M
251.30M
49.91M
172.18M
Valuation Measures
Feb 2022
PER 30.77 ROA 3.20% ROE 3.82% Operating margin 7.76% Profit margin 8.03%
Key executives
President & Representative Director:
Kazuhide Nakatomi
Director, Executive Officer, Manager-Finance & IR:
Shinichiro Takao
Senior Executive Officer, GM-R&D:
Takaaki Terahara
Director, Manager-Legal Affairs & Head-Compliance:
Nobuo Tsutsumi
MD, Executive Officer & Head-Operations:
Tetsuo Akiyama Shareholders
Hisamitsu Pharmaceutical Co., Inc. (7.4%)
Nishi Nippon City Bank Pension Fund (5.1%)
MUFG Bank Pension Fund (5.0%)
Nippon Life Insurance Co. (4.5%)
Government of Japan (4.0%)
Fukuoka Financial Group, Inc. (3.9%)
Hisamitsu Pharmaceutical Business Association (2.8%)
The Bank of Saga Ltd. (2.7%)
Sumitomo Mitsui Banking Pension Fund (2.4%)
Mitsubishi UFJ Financial Group, Inc. (2.1%)
Related Companies
Hisamitsu Italia Srl
Hisamitsu Agency Co., Ltd
Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
Hisamitsu Pharmaceutical (China) Co., Ltd.
Nakatomi Memorial Foundation
Hisamitsu Pharmaceutical Co., Ltd
Hisamitsu Farmaceutica do Brasil Ltda.
Hisamitsu Vietnam Pharmaceutical Co., Ltd.
PT Hisamitsu Pharma Indonesia
Hisamitsu UK Ltd.
Hisamitsu Pharmaceutical Business Association
Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co., Ltd.
CRCC Media Co., Ltd.
Hisamitsu America, Inc.
Saga City-Vision Co., Ltd.
Hisamitsu U.S., Inc.
SSP Co. Ltd. /Ethical Medicine Division/
Taiyo Co., Ltd
Noven Pharmaceuticals, Inc.
Competitors
KemPharm, Inc.
Icure Pharmaceutical Incorporation
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Jan, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
